Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Monday, October 22, 2012

New Hepatitis B Vaccine Induces Higher Seroprotection Rates Than Engerix-B

SAN DIEGO, CA—Two doses of the investigational hepatitis B vaccine, HEPLISAV, administered over 4 weeks induced significantly higher rates of and earlier seroprotection than Engerix-B given as 3 doses over 24 weeks, results of two pivotal Phase 3 trials concluded at IDWeek 2012.

Two multicenter trials of the two vaccines were conducted to determine immunogenicity in subjects in the age range for the proposed indication for HEPLISAV, noted Robert Janssen, MD, from Dynavax Technologies, Berkeley, CA. Dynavax has submitted a Biologics License Application to the U.S. Food and Drug Administration for an indication of prevention of hepatitis B infection in individuals 18 to 70 years old.


No comments:

Post a Comment